Journal ArticleDOI
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Reads0
Chats0
TLDR
The data suggest that high TAM score is associated with a favorable prognosis in FL patients treated with immunochemotherapy, and high TAM content remained an independent prognostic factor for OS and PFS.Abstract:
Purpose: Tumor-associated macrophage (TAM) content predicts survival in follicular lymphoma (FL) patients treated with chemotherapy The aim of this study was to determine how combination of rituximab with chemotherapy influences TAM-associated clinical outcome
Experimental Design: Expression of a macrophage marker, CD68, was determined immunohistochemically from FL samples of 96 patients treated with rituximab and cyclophosphamide-Adriamycin-vincristine-prednisone regimen Of them, 71 received therapy at diagnosis and 25 at relapse Neutrophil and CD3+ lymphocyte counts were also measured The median follow-up time for the cohort was 54 months Fourty-five patients previously treated with chemotherapy served as a control group
Results: Consistent with previous studies, high TAM amount was associated with adverse outcome in chemotherapy-treated patients ( P = 0026) In contrast, after rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone regimen, high TAM content correlated with longer survival rates According to Kaplan Meier estimates, the median progression free survival (PFS) was not reached for patients with high TAM content compared with 45 months for patients with low TAM scores ( P = 0006) A trend toward a better overall survival (OS) at 5 years was also observed for patients with high TAM content (OS, 97% versus 90%, P = 0116) The positive prognostic value of TAMs was seen both for the patients treated at diagnosis and at relapse In multivariate analyses, TAM content remained an independent prognostic factor for OS and PFS Neutrophil and CD3+ lymphocyte counts did not correlate with outcome
Conclusions: The data suggest that high TAM score is associated with a favorable prognosis in FL patients treated with immunochemotherapyread more
Citations
More filters
Journal ArticleDOI
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.
TL;DR: This work surmises that CRI represents the seventh hallmark of cancer, and suggests that an additional mechanism involved in cancer-related inflammation (CRI) is induction of genetic instability by inflammatory mediators, leading to accumulation of random genetic alterations in cancer cells.
Journal ArticleDOI
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani,Federica Marchesi,Federica Marchesi,Alberto Malesci,Alberto Malesci,Luigi Laghi,Paola Allavena +6 more
TL;DR: It is surmised that TAMs can provide tools to tailor the use of cytoreductive therapies and immunotherapy in a personalized medicine approach, and that TAM-focused therapeutic strategies have the potential to complement and synergize with both chemotherapy and immunotherapies.
Journal ArticleDOI
Macrophage Regulation of Tumor Responses to Anticancer Therapies
Michele De Palma,Claire E. Lewis +1 more
TL;DR: The biological significance and clinical implications of these findings are discussed, with an emphasis on novel approaches that effectively target TAMs to increase the efficacy of such therapies.
Journal ArticleDOI
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel,Lionel Apetoh,François Ghiringhelli,Fabrice Andre,Antoine Tesniere,Guido Kroemer +5 more
TL;DR: This Review addresses the question, How may it be possible to ameliorate conventional therapies by stimulating the anticancer immune response and discusses the rationale of clinical trials to evaluate and eventually increase the contribution of antitumor immune responses to the therapeutic management of neoplasia.
Journal ArticleDOI
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
TL;DR: The ‘macrophage balance’ is discussed in the context of the apparent paradox of tumor promotion by innate immunity‐driven inflammation and the seemingly opposed tumor surveillance by adaptive immune responses.
References
More filters
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Journal ArticleDOI
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
TL;DR: It is demonstrated that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner FcγRIIB.
Journal ArticleDOI
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
Journal ArticleDOI
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
Sandeep S. Dave,George E. Wright,Bruce K. Tan,Andreas Rosenwald,Andreas Rosenwald,Randy D. Gascoyne,Wing C. Chan,Richard I. Fisher,Rita M. Braziel,Lisa M. Rimsza,Thomas M. Grogan,Thomas P. Miller,Michael LeBlanc,Timothy C. Greiner,Dennis D. Weisenburger,James C. Lynch,Julie M. Vose,James O. Armitage,Erlend B. Smeland,Stein Kvaløy,Harald Holte,Jan Delabie,Joseph M. Connors,Peter M. Lansdorp,Qin Ouyang,T. Andrew Lister,Andrew Davies,Andrew J. Norton,H. Konrad Muller-Hermelink,German Ott,Elias Campo,Emilio Montserrat,Wyndham H. Wilson,Elaine S. Jaffe,Richard M. Simon,Liming Yang,John Powell,Hong Zhao,Neta Goldschmidt,Michael Chiorazzi,Louis M. Staudt +40 more
TL;DR: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis.
Journal ArticleDOI
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Wolfgang Hiddemann,Michael Kneba,Martin Dreyling,Norbert Schmitz,Eva Lengfelder,Rudolf Schmits,Marcel Reiser,Bernd Metzner,Harriet Harder,Susanna Hegewisch-Becker,Thomas M. Fischer,Martin Kropff,Hans-Edgar Reis,Mathias Freund,Bernhard Wörmann,Roland Fuchs,Manfred Planker,Jörg Schimke,Hartmut Eimermacher,Lorenz Trümper,Ali Aldaoud,Reza Parwaresch,Michael Unterhalt +22 more
TL;DR: Adding rituximab to CHOP significantly improves the outcome for patients with previously untreated advanced-stage FL and does not induce major adverse effects.
Related Papers (5)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
Sandeep S. Dave,George E. Wright,Bruce K. Tan,Andreas Rosenwald,Andreas Rosenwald,Randy D. Gascoyne,Wing C. Chan,Richard I. Fisher,Rita M. Braziel,Lisa M. Rimsza,Thomas M. Grogan,Thomas P. Miller,Michael LeBlanc,Timothy C. Greiner,Dennis D. Weisenburger,James C. Lynch,Julie M. Vose,James O. Armitage,Erlend B. Smeland,Stein Kvaløy,Harald Holte,Jan Delabie,Joseph M. Connors,Peter M. Lansdorp,Qin Ouyang,T. Andrew Lister,Andrew Davies,Andrew J. Norton,H. Konrad Muller-Hermelink,German Ott,Elias Campo,Emilio Montserrat,Wyndham H. Wilson,Elaine S. Jaffe,Richard M. Simon,Liming Yang,John Powell,Hong Zhao,Neta Goldschmidt,Michael Chiorazzi,Louis M. Staudt +40 more
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Christian Steidl,Tang Lee,Sohrab P. Shah,Pedro Farinha,Guangming Han,Tarun Nayar,Allen Delaney,Steven J.M. Jones,Javeed Iqbal,Dennis D. Weisenburger,Martin Bast,Andreas Rosenwald,Hans Konrad Müller-Hermelink,Lisa M. Rimsza,Elias Campo,Jan Delabie,Rita M. Braziel,James R. Cook,James R. Cook,Raymond R. Tubbs,Raymond R. Tubbs,Elaine S. Jaffe,Georg Lenz,Joseph M. Connors,Louis M. Staudt,Wing C. Chan,Randy D. Gascoyne +26 more